Novartis announced that the U.S. FDA has approved the dual combination bronchodilator Utibron™ Neohaler®(indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD. COPD is a progressive and life-threatening lung disease that makes it difficult to breathe. Nearly 27 million people in the US are affected by COPD, which ranks as the third leading cause of death in the US and is a major cause of serious long-term disability. Novartis expects that Utibron Neohaler will be available in the first quarter of 2016.